Catalyst Dossier · compiled by Celia 🧫

AstraZeneca PLC (AZN)

Pharmaceutical Preparations · market cap $273.6B · as of 2026-06-23

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-07 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

AstraZeneca PLC (AZN) is a Swedish-British multinational pharmaceutical and biotechnology company headquartered in Cambridge, UK, with a market cap of approximately $274 billion and ~89,900 employees. The company operates across oncology, cardiovascular, respiratory, gastrointestinal, and other therapeutic areas, with a deep late-stage pipeline spanning multiple Phase 3 programs. Near-term catalysts are concentrated in oncology, with high-importance Phase 3 readouts for Osimertinib and Olaparib expected in July and September 2026.

The catalyst path

2026-07-07 (est.)Phase 3 · Osimertinibimp 9/10
2026-07-24 (est.)Phase 2 · AZD9550imp 7/10
2026-07-27 (est.)Phase 3 · Olaparibimp 9/10
2026-07-31 (est.)Phase 2 · Dapagliflozinimp 7/10
2026-08-04Earningsimp 5/10
2026-08-19 (est.)Phase 2 · Capecitabineimp 7/10
2026-09-28 (est.)Phase 2 · AZD0901imp 7/10
2026-09-30 (est.)Phase 2 · AZD0780imp 7/10

Pipeline

Asset	Phase	Indication
AZD1152	Phase 3	Acute Myeloid Leukemia
Symbicort pMDI + budesonide HFA pMDI	Phase 3	Asthma
AC2993 (exenatide)	Phase 2	Diabetes Mellitus
AZD6234	Phase 2	Obesity/Overweight
MEDI6570	Phase 2	Coronary Heart Disease (CHD)
Tremelimumab monotherapy	Phase 2	Urothelial Bladder Cancer
B - Exenatide 10 mcg twice daily	Phase 2	Diabetes Mellitus, Type 2
Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate	Phase 3	Chronic Obstructive Pulmonary Disease
ZD1839	Phase 2	Mesothelioma
Chemotherapy	Phase 3	Anticancer Treatment
Saruparib (AZD5305)	Phase 3	Ovarian Cancer
Esomeprazole IV	Phase 3	Gastrointestinal Hemorrhage
Ticagrelor Dose 1a + Dose 2a	Phase 2	Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease
exenatide twice daily	Phase 3	Type 2 Diabetes Mellitus
Ciclesonide nasal	Phase 3	Rhinitis, Allergic, Perennial
SBC-103	Phase 2	Mucopolysaccharidosis IIIB
fostamatinib	Phase 3	Rheumatoid Arthritis
AZD3470	Phase 2	Lymphoma
Benralizumab Arm B	Phase 3	Moderate to Very Severe Chronic Obstructive Pulmonary Disease
D961H capsule 10mg	Phase 3	Reflux Esophagitis

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by Celia. The catalyst path & pipeline above are free.

See Pro

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by Celia. Not financial advice.